Nucleic acid molecules encoding glutx and uses thereof
AssigneeMillennium Pharmaceuticals, Inc., a Delaware corporation
InventorsLouis A. Tartaglia, Xun Weng
Life of this patent
Estimating the term…
Abstract
The invention concerns the human gene encoding GLUTX, a glucose transporter. GLUTX nucleic acid and polypeptides, as well as molecules which increase or decrease expression or activity of GLUTX, are useful in the diagnosis and treatment of disorders associated with aberrant hexose transport.
Claims32
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- and
- b) a nucleic acid molecule which encodes at least 15 contiguous amino acids of SEQ ID NO:2.
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- a) the nucleotide sequence of SEQ ID NO:1;
- b) the nucleotide sequence of SEQ ID NO:1;
- wherein all T nucleotides are replaced by U nucleotides;
- c) a nucleotide sequence complementary to (a) or (b);
- and
- d) a fragment of (a), (b), or (c) that is at least 25 nucleotides in length.
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule which encodes a polypeptide that is at least 80% identical to SEQ ID NO:2;
- b) a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the sequence of SEQ ID NO:1;
- and
- c) a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid having the cDNA sequence contained within ATCC Accession No. ______.
A substantially pure polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- and
- b) a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:2.
A substantially pure polypeptide selected from the group consisting of:
- a) a polypeptide encoded by a nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of SEQ ID NO:1;
- b) a polypeptide encoded by a nucleic acid molecule that hybridizes under stringent conditions to the cDNA sequence contained within ATCC Accession No. ______.
A method for detecting the presence of a nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- b) a nucleic acid molecule which encodes at least 15 contiguous amino acids of SEQ ID NO:2;
- in a sample, the method comprising the steps of:
- i) contacting the sample with a nucleic acid probe which selectively hybridizes to the nucleic acid molecule;
- and
- ii) determining whether the nucleic acid probe binds to the nucleic acid molecule in the sample.
A method for producing a substantially pure polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- and
- b) a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:2;
- the method comprising the step of culturing a host cell containing the nucleic acid molecule encoding the polypeptide under conditions in which the nucleic acid molecule is expressed.
A method for detecting the presence of a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- and
- b) a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:2;
- in a biological sample, the method comprising the steps of:
- i) contacting the sample with a compound which selectively binds to the polypeptide;
- and
- ii) determining whether the compound binds to the polypeptide in the sample.
A method for identifying a compound which binds tc a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- and
- b) a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:2;
- the method comprising the steps of:
- i) contacting the polypeptide with a test compound;
- and
- ii) determining whether the polypeptide binds to the test compound.
A method for modulating the activity of a polypeptide selected from:
- a) a polypeptide comprising having amino acid sequence of SEQ ID NO:2;
- and
- b) a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:2;
- the method comprising contacting a cell expressing the polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
A method of identifying a compound that modulates the expression of a gene encoding GLUTX, the method comprising the steps of:
- a) contacting a cell expressing a gene with a test compound;
- and
- b) detecting the level of expression of the gene in the presence of the test compound, wherein a difference in expression in the presence of the test compound compared to expression in the absence of the test compound indicates that the test compound modulates expression of the gene.
A method of identifying a compound that modulates the activity of GLUTX, the method comprising the steps of:
- a) contacting the polypeptide with a test compound;
- and
- b) detecting the level of activity of GLUTX having the amino acid sequence of SEQ ID NO:2 in the presence of the test compound, wherein a difference in activity in the presence of the test compound compared to the activity in the absence of the test compound indicates that the test compound modulates the activity of GLUTX.
A method for modulating hexose uptake, the method comprising modulating the expression or activity of a gene encoding the amino acid sequence of SEQ ID NO:2.
A method for treating a patient having a disorder associated with aberrant expression or activity of a gene encoding the amino acid sequence of SEQ ID NO:2, the method comprising administering a therapeutically effective amount of a compound that decreases the expression or activity of the gene.
A method for treating a patient having a disorder associated with aberrant expression or activity of a GLUTX polypeptide comprising the amino acid sequence of SEQ ID NO:2, the method comprising administering a therapeutically effective amount of a compound that increases the expression or activity of the gene.
A method for diagnosing a patient as having a disorder associated with aberrant expression of GLUTX, comprising measuring expression of a GLUTX polypeptide having the sequence of SEQ ID NO:2 in a biological sample obtained from the patient, wherein increased or decreased GLUTX expression in the biological sample, compared with GLUTX expression in a control sample, indicates that the patient has a disorder associated with aberrant expression of GLUTX.
A method for diagnosing a patient as having a disorder associated with expression of an isoform of GLUTX, comprising isolating GLUTX mRNA or GLUTX polypeptide from the patient and determining the sequence of the mRNA or polypeptide, a difference in the sequence, as compared to the nucleotide sequence of SEQ ID NO:l or the polypeptide sequence of SEQ ID NO:2, respectively, indicating expression of an isoform of GLUTX.
A method for diagnosing a patient as having a disorder associated with aberrant activity of GLUTX, comprising measuring the activity of a GLUTX polypeptide having the amino acid sequence of SEQ ID NO:2 in a biological sample obtained from the patient, wherein increased or decreased GLUTX activity in the biological sample, compared with GLUTX activity in a control sample, indicates that the patient has a disorder associated with aberrant activity of GLUTX.
Dependencies are inferred from the claim text.